company background image
2170 logo

Suzhou Basecare Medical SEHK:2170 Stock Report

Last Price

HK$1.92

Market Cap

HK$510.5m

7D

-2.5%

1Y

-56.8%

Updated

17 Apr, 2024

Data

Company Financials +

Suzhou Basecare Medical Corporation Limited

SEHK:2170 Stock Report

Market Cap: HK$510.5m

2170 Stock Overview

Suzhou Basecare Medical Corporation Limited, an investment holding company, engages in the research, development, manufacture, and provision of genetic testing solutions for assisted human reproduction and sale of genetic testing devices and instruments in the People’s Republic of China.

2170 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Suzhou Basecare Medical Corporation Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Suzhou Basecare Medical
Historical stock prices
Current Share PriceHK$1.92
52 Week HighHK$4.94
52 Week LowHK$1.83
Beta0.55
1 Month Change-9.43%
3 Month Change-11.52%
1 Year Change-56.76%
3 Year Change-91.21%
5 Year Changen/a
Change since IPO-93.07%

Recent News & Updates

Suzhou Basecare Medical Corporation Limited (HKG:2170) Screens Well But There Might Be A Catch

Mar 22
Suzhou Basecare Medical Corporation Limited (HKG:2170) Screens Well But There Might Be A Catch

Recent updates

Suzhou Basecare Medical Corporation Limited (HKG:2170) Screens Well But There Might Be A Catch

Mar 22
Suzhou Basecare Medical Corporation Limited (HKG:2170) Screens Well But There Might Be A Catch

Is There An Opportunity With Suzhou Basecare Medical Corporation Limited's (HKG:2170) 47% Undervaluation?

Aug 01
Is There An Opportunity With Suzhou Basecare Medical Corporation Limited's (HKG:2170) 47% Undervaluation?

Lacklustre Performance Is Driving Suzhou Basecare Medical Corporation Limited's (HKG:2170) 27% Price Drop

May 26
Lacklustre Performance Is Driving Suzhou Basecare Medical Corporation Limited's (HKG:2170) 27% Price Drop

Are Investors Undervaluing Suzhou Basecare Medical Corporation Limited (HKG:2170) By 48%?

Jul 20
Are Investors Undervaluing Suzhou Basecare Medical Corporation Limited (HKG:2170) By 48%?

Shareholder Returns

2170HK Medical EquipmentHK Market
7D-2.5%-4.0%-2.8%
1Y-56.8%-54.0%-15.0%

Return vs Industry: 2170 underperformed the Hong Kong Medical Equipment industry which returned -54.6% over the past year.

Return vs Market: 2170 underperformed the Hong Kong Market which returned -16.4% over the past year.

Price Volatility

Is 2170's price volatile compared to industry and market?
2170 volatility
2170 Average Weekly Movement7.4%
Medical Equipment Industry Average Movement7.2%
Market Average Movement7.4%
10% most volatile stocks in HK Market14.8%
10% least volatile stocks in HK Market3.8%

Stable Share Price: 2170 has not had significant price volatility in the past 3 months.

Volatility Over Time: 2170's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2010586Bo Liangwww.basecare.cn

Suzhou Basecare Medical Corporation Limited, an investment holding company, engages in the research, development, manufacture, and provision of genetic testing solutions for assisted human reproduction and sale of genetic testing devices and instruments in the People’s Republic of China. The company offers genetic test kit products, which include pre-implantation genetic test kits, such as PGT-A to detect aneuploidy; PGT-M to detect single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kits to detect chromosome structural rearrangements, which are common causes of recurrent miscarriage. It also provides CNV kits, a reagent kit to test abortive tissues for a comprehensive panel of copy number variations for miscarriage.

Suzhou Basecare Medical Corporation Limited Fundamentals Summary

How do Suzhou Basecare Medical's earnings and revenue compare to its market cap?
2170 fundamental statistics
Market capHK$510.52m
Earnings (TTM)-HK$207.40m
Revenue (TTM)HK$225.02m

2.3x

P/S Ratio

-2.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2170 income statement (TTM)
RevenueCN¥207.98m
Cost of RevenueCN¥116.63m
Gross ProfitCN¥91.35m
Other ExpensesCN¥283.04m
Earnings-CN¥191.68m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.72
Gross Margin43.92%
Net Profit Margin-92.17%
Debt/Equity Ratio19.3%

How did 2170 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.